By Ludwig Burger and Maggie Fick (Reuters) - Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk (CSE:NOVOb)'s Wegovy can...
By Ludwig Burger FRANKFURT (Reuters) - Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage,...
Healthcare stocks are generally more resilient in an uncertain macro backdrop, given the essential nature of products and services offered by the companies in this space. Using...
The U.S. stock market is on track for its worst year since 2008, with the S&P 500 down 19.6% year-to-date. The market’s trajectory in 2023 will continue to be dictated by...
Biogen stock is getting favorable ratings after successful trial results for its latest Alzheimer's treatment Lecanemab is Biogen's latest attempt to cure the disease after its...
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups for service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in over 110 countries.
| Average | 440.83 (-0.97% Downside) |
| High | 507.00 |
| Low | 312.00 |
| Price | 445.13 |
| No. of Analysts | 25 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Buy | Neutral | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 96.00 | 96.00 | 96.00 | 0.00 | 0.00% | 0.00 | London | |||
| 99.00 | 99.20 | 99.00 | -0.20 | -0.20% | 114.27K | London | |||
| 8.75 | 8.75 | 8.75 | -0.5000 | -5.41% | 1.11M | London | |||
| 75.00 | 75.00 | 75.00 | 0.00 | 0.00% | 0.00 | London | |||
| 4.25 | 4.25 | 4.25 | 0.00 | 0.00% | 158.78K | London | |||
| 36.00 | 36.00 | 32.04 | 0.00 | 0.00% | 0.00 | London | |||
| 101.75 | 101.75 | 101.75 | 0.00 | 0.00% | 0.00 | London | |||
| 98.50 | 98.50 | 98.50 | 0.00 | 0.00% | 0.00 | London | |||
| 6.00 | 6.10 | 6.00 | -0.100 | -1.64% | 3.61M | London | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00% | 0.00 | London | |||
| 5.05 | 5.05 | 5.05 | +0.15 | +3.06% | 209.86K | London | |||
| 88.50 | 89.20 | 89.20 | +0.50 | +0.57% | 261.47K | London | |||
| 70.00 | 70.00 | 70.00 | 0.00 | 0.00% | 30.13K | London | |||
| 0.305 | 0.30 | 0.30 | 0.00 | 0.00% | 840.40K | London | |||
| 12.875 | 12.875 | 12.875 | 0.00 | 0.00% | 0.00 | London |